2026.

• Mar.09.2026 Sustainability

  Ono Pharma Selected as "2026 Health & Productivity Stock"

• Mar.05.2026 Management / Finance

  Notice Concerning Disposal of Treasury Shares by Third-Party Allotment

• Mar.05.2026 Corporate

  Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary

• Mar.03.2026 Licensing

  Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

• Mar.02.2026 Products

  Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment to Daito Pharmaceutical Co., Ltd.

• Mar.02.2026 Corporate

  Announcement on Changes of the Board of Directors and Corporate Officers

• Feb.27.2026 Products

  Announcement concerning the Transfer of Distribution, Sales and Termination of Co-promotion for SGLT2 Inhibitor “Forxiga® 5 mg, 10 mg Tablets’’ in Japan

• Feb.24.2026 R & D

  Opdivo® (nivolumab) Intravenous Infusion Approved in South Korea in Combination with Yervoy® (ipilimumab) for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

• Feb.16.2026 R & D

  Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

• Feb.02.2026 Management / Finance

  Announcement on Financial Results for FY2025 Q3

• Jan.14.2026 R & D

  Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

• Jan.13.2026 R & D

  Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea